Journal of the American College of Cardiology
-
J. Am. Coll. Cardiol. · May 2010
Case Reports Biography Historical ArticleJ waves of Osborn revisited.
-
J. Am. Coll. Cardiol. · May 2010
Controlled Clinical TrialElevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism.
We assessed the predictive value of heart-type fatty acid-binding protein (H-FABP) in normotensive patients with acute pulmonary embolism (PE). ⋯ The H-FABP might be a useful biomarker for risk stratification of normotensive patients with acute PE.
-
J. Am. Coll. Cardiol. · May 2010
Multicenter Study Controlled Clinical TrialCopeptin improves early diagnosis of acute myocardial infarction.
Early identification of myocardial infarction in chest pain patients is crucial to identify patients at risk and to maintain a fast treatment initiation. ⋯ In triage of chest pain patients, determination of copeptin in addition to troponin improves diagnostic performance, especially early after CPO. Combined determination of troponin and copeptin provides a remarkable negative predictive value virtually independent of CPO time and therefore aids in early and safe rule-out of myocardial infarction.
-
J. Am. Coll. Cardiol. · May 2010
Randomized Controlled TrialProspective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I.
The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac troponin I (cTnI) using a current-generation sensitive assay in patients with suspected acute coronary syndrome (ACS). ⋯ Low-level increases in cTnI using a sensitive assay identify patients at higher risk of death or MI. These findings support current American College of Cardiology/American Heart Association recommendations defining MI, and the incremental value of newer, more sensitive assays in identifying high-risk patients with ACS.
-
J. Am. Coll. Cardiol. · May 2010
Multicenter Study Clinical TrialMid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
Our purpose was to assess the diagnostic utility of mid-regional pro-atrial natriuretic peptide (MR-proANP) for the diagnosis of acute heart failure (AHF) and the prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with AHF. ⋯ MR-proANP is as useful as BNP for AHF diagnosis in dyspneic patients and may provide additional clinical utility when BNP is difficult to interpret. MR-proADM identifies patients with high 90-day mortality risk and adds prognostic value to BNP. (Biomarkers in Acute Heart Failure [BACH]; NCT00537628).